Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Cláudio de Figueiredo Mendes"'
Autor:
Mario Guimarães Pessoa, ISABEL VELOSO ALVES PEREIRA, Patricia Momoyo Yoshimura Zitelli, Mísia Joyner de Sousa Dias Monteiro, Claudia Couto, Juliana Souza de Oliveira, Ana Beatriz Souza de Oliveira, José Tadeu Stefano, Renato Altikes, Ana Luiza Gomes Reis, Ana Carolina Ferreira Netto Cardoso, Cláudio de Figueiredo Mendes, Lais Arrivabene Barbieri, Nathalie C. Leite, Cristiane A. Villela-Nogueira, Claudia P Oliveira
Publikováno v:
Annals of Hepatology, Vol 29, Iss , Pp 101710- (2024)
Conflict of interest: No Introduction and Objectives: Pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, has shown efficacy in improving indirect markers of liver steatosis, inflammation, and fibrosis. It also addresses sys
Externí odkaz:
https://doaj.org/article/ce775582518e489aa1f5f4e94bc432e7
Autor:
Ana Carolina Cardoso, Cristiane A. Villela-Nogueira, Cláudio de Figueiredo-Mendes, Hilton Leão Filho, Rogério Augusto Pinto Silva, Cristiane Valle Tovo, Hugo Perazzo, Antonio Carlos Matteoni, Roberto José de Carvalho-Filho, Paulo Lisboa Bittencourt
Publikováno v:
Annals of Hepatology, Vol 22, Iss , Pp 100341- (2021)
In 2015 the European Association for the Study of Liver Diseases (EASL) and the Asociación Latinoamericana para el Estudio del Hígado (ALEH) published a guideline for the use of non-invasive markers of liver disease. At that time, this guideline fo
Externí odkaz:
https://doaj.org/article/721a11215f20438eb5dbfb5cb9524c2d
Autor:
George Bakalos, Stephen D. Shafran, Fernando Tatsch, Thomas Berg, Hugo Cheinquer, Maria Cassia Mendes-Correa, Mitchell L. Shiffman, Alma Minerva Perez Rios, Arun J. Sanyal, Gregory J. Dore, Stefan Zeuzem, Christoph P. Berg, Tania Reuter, Edison Roberto Parise, Marc Hohmann, Maria Lucia Gomes Ferraz, Maria Patelli J.S. Lima, Cláudio de Figueiredo-Mendes
Publikováno v:
Hepatology international. 8(4)
The combination of pegylated interferon alfa/ribavirin will likely remain the treatment of choice for HCV genotype 2/3 patients in financially constrained countries for the foreseeable future. Patients with poor on-treatment response may benefit from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd3bdecb5c8aed5cec4ad1bdfee701d
https://pubmed.ncbi.nlm.nih.gov/26202757
https://pubmed.ncbi.nlm.nih.gov/26202757